1. 1315PDevelopment and internal validation of a predictive nomogram of progression-free survival in well-differentiated stage IV gastroenteropancreatic neuroendocrine tumours treated with somatostatin analogues: GETNE-TRASGU study. (23rd October 2018) Authors: Garcia-Carbonero, R; Alonso, V; Capdevila, J; Sanchez Canovas, M; Alonso, T; Benavent, M; Custodio, A; Crespo Herrero, G; Lopez, C; Hernando, J; Riesco Martinez, M C; Escudero, P; Gallego Plazas, J; Marazuela, M; Diaz, J A; Llanos-Munoz, M; La Casta, A; Percovich, J C; Jimenez-Fonseca, P; Carmona... Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1329PEfficacy and safety of vandetanib for patients with advanced and progressive medullary thyroid cancer (MTC) as systemic treatment beyond first-line therapy. (23rd October 2018) Authors: Hernando Cubero, J; Grande, E; Jimenez Fonseca, P; Villabona, C; Trigo Perez, J M; Martinez Trufero, J; Pajares Bernad, I; Lopez, C; Alonso, T; Biarnes, J; Ramón, T; Cajal, Y; Duran, M; Grau, J J; Arevalo Lobera, S; Mesia Nin, R; Llanos, M; Dalmau Portulas, E; Alvarez, C; Zafon, C Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 478PIn the pathway to response: Is aflibercept an optimal treatment for RASwt mCRC patients after progression to 1st line containing anti-EGFR?. (23rd October 2018) Authors: Mata Velasco, E; González-Flores, E; Juez Martel, I; Alonso, V; Iranzo Gomez, P; Martinez Lago, N; Lopez, C; Cabrera Romero, J M; Safont Aguilera, M J; Ruiz Casado, A; Salgado Fernandez, M; González Astorga, B; Escudero, P; Rivera Herrero, F; Pericay Pijaume, C; Vera, R Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 4CPS-023 Long term efficacy, safety and adherence to alirocumab in patients with dyslipidaemia from a tertiary hospital cohort. (24th March 2020) Authors: Rodriguez, A; Lopez, C; González-Colominas, E; Luque, S; Recasens, L; Pedro-Botet, J; Oliveras, A; Gonzalez, R; Tarason, L; Grau, S Journal: European journal of hospital pharmacy Issue: Volume 27(2020)Supplement 1 Page Start: A57 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P-146Immune modulatory effects of ibrutinib in pancreatic ductal adenocarcinoma. (2nd July 2019) Authors: Sinha, M; Griffith, M; Betts, C; Choe, G; Sivagnanam, S; Cheung, A; Tamaki, W; Liu, E; Sudduth-Klinger, J; Vaccaro, G; Lopez, C; Fong, L; Coussens, L; Tempero, M Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P166 Measures of overnight sleep stability in patients with hypersomnolence. (7th October 2021) Authors: Woods, S; Frenkel, S; Lopez, C; Murnane, C; Southcott, A Journal: Sleep advances Issue: Volume 2:Supplement 1(2021) Page Start: A75 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P419 Clinical effectiveness and safety of first-line biologic vedolizumab as a monotherapy or combination therapy in ulcerative colitis and Crohn's disease patients: results from the EVOLVE study. (15th January 2020) Authors: Bressler, B; Yarur, A; Kopylov, U; Bassel, M; Brett, N; Colby, C; Lopez, C; Saha, S; Kifnidi, C; Agboton, C; Adsul, S; Demuth, D; Luo, M; Wang, S; Mantzaris, G J Journal: Journal of Crohn's and colitis Issue: Volume 14(2020)Supplement 1 Page Start: S381 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P573 Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive ulcerative colitis patients: Results from the EVOLVE study. (25th January 2019) Authors: Yarur, A; Mantzaris, G; Silverberg, M; Walshe, M; Zezos, P; Stein, D; Bassel, M; Lissoos, T; Lopez, C; Natsios, A; Radulescu, G; Patel, H; Demuth, D; Bressler, B Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S400 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P621 Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive Crohn's disease patients: results from the EVOLVE study. (25th January 2019) Authors: Bressler, B; Mantzaris, G; Silverberg, M; Zezos, P; Stein, D; Colby, C; Lissoos, T; Lopez, C; Natsios, A; Radulescu, G; Patel, H; Demuth, D; Yarur, A Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S427 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P632 Etrasimod induction therapy in moderately to severely active Crohn's disease: results from a phase 2, randomised, double-blind substudy. (30th January 2023) Authors: D'Haens, G; Dubinsky, M C; Peyrin-Biroulet, L; Danese, S; Sands, B E; Wolf, D C; Yarur, A; Chiorean, M; Dray, D; Modesto, I; Tan, H; Gu, G; Lopez, C; Su, C; Zhang, J; Cataldi, F; McDonnell, A; Schreiber, S; Feagan, B G; Vermeire, S Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i764 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗